InMed Pharmaceuticals Inc. (INM) Earnings History
Annual and quarterly earnings data from 2001 to 2025
Loading earnings history...
INM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
INM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 34.5% | -160.2% | -165.1% |
| 2024 | 23.9% | -176.9% | -166.9% |
| 2023 | 33.9% | -202.6% | -192.2% |
| 2022 | 49.9% | -1266.0% | -1707.3% |
| 2021 | - | - | - |
Download Data
Export INM earnings history in CSV or JSON format
Free sign-in required to download data
InMed Pharmaceuticals Inc. (INM) Earnings Overview
As of May 8, 2026, InMed Pharmaceuticals Inc. (INM) reported trailing twelve-month net income of -$9M, reflecting +58.5% year-over-year growth. The company earned $-2293.04 per diluted share over the past four quarters, with a net profit margin of -165.1%.
Looking at the long-term picture, INM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$46,737 in fiscal 2013.
InMed Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including YCBD (-$328M net income, -10.6% margin), ATAI (-$154M net income, -48464.0% margin), MNMD (-$238M net income), INM has room to improve margins relative to the peer group. Compare INM vs YCBD →
INM Earnings vs Peers
Earnings metrics vs comparable public companies
INM Historical Earnings Data (2001–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | -6.3% | -$8M | $-11.44 | -165.1% | -160.2% |
| 2024 | -$8M | +3.4% | -$8M | $-27.55 | -166.9% | -176.9% |
| 2023 | -$8M | +57.3% | -$8M | $-86.00 | -192.2% | -202.6% |
| 2022 | -$19M | -47.0% | -$14M | $-21350.51 | -1707.3% | -1266.0% |
| 2021 | -$13M | -41.5% | -$12M | $-938.91 | - | - |
| 2020 | -$9M | +10.7% | -$9M | $-1161.21 | - | - |
| 2019 | -$10M | -49.2% | -$10M | $-1264.97 | - | - |
| 2018 | -$7M | -95.0% | -$7M | $-1032.30 | - | - |
| 2017 | -$3M | -87.2% | -$3M | $-810.55 | - | - |
| 2016 | -$2M | +46.9% | -$2M | $-643.57 | - | - |
See INM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINM — Frequently Asked Questions
Quick answers to the most common questions about buying INM stock.
Is INM growing earnings?
INM EPS is $-2293.04, with earnings growth accelerating to +58.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are INM's profit margins?
InMed Pharmaceuticals Inc. net margin is -165.1%, with operating margin at -160.2%. Below-average margins reflect competitive or cost pressures.
How consistent are INM's earnings?
INM earnings data spans 2001-2025. The accelerating earnings trend is +58.5% YoY. Historical data enables comparison across business cycles.